Peptide Monograph
Thymosin Alpha-1
Zadaxin (Thymalfasin)
At a Glance
Mechanism of Action
Thymosin alpha-1 (Ta1) is a naturally occurring 28-amino acid peptide originally isolated from thymic tissue (thymosin fraction 5) by Goldstein et al. It is produced endogenously by thymic epithelial cells and is a key mediator of thymic immune education and peripheral immune regulation.[1]
Ta1 functions as an immune homeostatic regulator rather than a simple immune stimulant. Its primary immunological effects include enhancement of T-cell maturation and differentiation, particularly the maturation of immature T-cell precursors (thymocytes) into functional CD4+ and CD8+ T lymphocytes. This action is particularly relevant in immunocompromised states where T-cell function is diminished, such as chronic viral hepatitis, cancer, and aging-related immune decline (immunosenescence).[1][2]
At the molecular level, Ta1 stimulates toll-like receptors TLR2 and TLR9 on dendritic cells and other antigen-presenting cells. Activation of these pattern recognition receptors enhances the innate immune response and promotes dendritic cell maturation, improving antigen presentation and bridging innate and adaptive immunity.[2]
Ta1 augments natural killer (NK) cell activity, enhancing the ability of NK cells to recognize and destroy virally infected and malignant cells. It also promotes dendritic cell maturation, improving the efficiency of antigen processing and presentation to T cells.[2]
A critical aspect of Ta1's mechanism is its modulation of cytokine balance. Ta1 promotes a shift toward Th1 (cell-mediated) immune responses while maintaining Th2 (humoral) balance. It increases production of interferon-alpha (IFN-a), interleukin-2 (IL-2), and interleukin-12 (IL-12), which promote cellular immunity, while modulating pro-inflammatory cytokine production to prevent excessive inflammation. This immunomodulatory, rather than purely immunostimulatory, profile distinguishes Ta1 from many other immune-enhancing agents.[1][3]
Ta1 has also been shown to restore immune homeostasis in states of immune dysregulation, reducing excessive inflammation while simultaneously boosting impaired immune surveillance. This bidirectional capacity makes it a candidate for conditions ranging from chronic infections (where immune response is insufficient) to sepsis (where immune dysregulation causes excessive inflammation).[3]
Evidence Summary
Thymosin alpha-1 has an extensive clinical evidence base compared to most peptides on this site. It is approved in over 35 countries for hepatitis B and as a cancer immunotherapy adjunct, and has been studied in multiple Phase 2/3 trials. However, it is not FDA-approved, and the quality of some clinical trials has been questioned by Western regulatory standards.
Hepatitis B and C
The most robust clinical evidence for Ta1 is in the treatment of chronic hepatitis B. Multiple randomized controlled trials have demonstrated that Ta1, alone or in combination with interferon-alpha, significantly improves HBeAg seroconversion rates (a marker of immune control over hepatitis B virus) compared to interferon alone or placebo. A meta-analysis of clinical trials showed that Ta1 monotherapy achieved sustained virological response in approximately 26–40% of chronic hepatitis B patients.[3][5]
For hepatitis C, Ta1 has been studied as an adjunct to interferon-based therapy, with some trials showing improved sustained virological response rates when added to standard treatment regimens. However, with the advent of direct-acting antivirals (DAAs) for hepatitis C, the clinical relevance of Ta1 in HCV has diminished.[3]
Cancer Immunotherapy
Ta1 has been investigated as an adjunct to cancer immunotherapy and chemotherapy. Garaci et al. and others demonstrated that Ta1 can enhance the antitumor immune response when combined with standard chemotherapy or immunotherapy regimens. Clinical studies in hepatocellular carcinoma, non-small cell lung cancer, and melanoma have shown improvements in immune parameters and, in some studies, survival outcomes when Ta1 is added to standard treatment.[3]
COVID-19
During the COVID-19 pandemic, Ta1 was used as an adjunctive therapy in Chinese hospitals for critically ill patients with lymphopenia (low T-cell counts). Liu et al. reported that Ta1 treatment was associated with improved T-cell recovery and reduced mortality in a retrospective study of severe COVID-19 patients, though the study design was observational and subject to significant confounding.[4]
Other Applications
Additional areas of clinical investigation include primary immunodeficiency states, post-surgical immune recovery, vaccine adjuvant enhancement (improving vaccine response rates in immunocompromised populations), and sepsis (where Ta1's immunomodulatory properties may help restore immune homeostasis).[5]
Primary Uses
Based on the available clinical literature and regulatory approvals, thymosin alpha-1 is used or investigated for the following applications:
- Chronic hepatitis B — Approved indication in 35+ countries. Improves HBeAg seroconversion as monotherapy or in combination with interferon-alpha.[3]
- Chronic hepatitis C — Adjunctive use with interferon-based therapy (less relevant since DAA era).[3]
- Cancer immunotherapy adjunct — Enhancement of antitumor immunity when combined with chemotherapy or immunotherapy in hepatocellular carcinoma, NSCLC, and melanoma.[3]
- Immune restoration — Restoration of T-cell function in immunocompromised states, including post-chemotherapy, post-surgical, and aging-related immune decline.[1]
- Vaccine enhancement — Adjuvant to improve vaccine response rates in elderly and immunocompromised populations.[5]
- Severe infections — Adjunctive immune support in severe infections including COVID-19, sepsis, and opportunistic infections in immunocompromised patients.[4]
Contraindications
While thymosin alpha-1 has an established safety profile from clinical use in many countries, the following contraindications and precautions apply:
- Organ transplant recipients — Ta1 enhances T-cell function and immune surveillance. In organ transplant recipients on immunosuppressive therapy, immune activation by Ta1 could increase the risk of graft rejection. Use is contraindicated unless under direct transplant specialist supervision.
- Active autoimmune disease — Ta1's immune-enhancing properties could theoretically exacerbate autoimmune conditions such as lupus, rheumatoid arthritis, or multiple sclerosis by augmenting the autoreactive immune response. Use with extreme caution, if at all, in active autoimmune disease.
- Pregnancy and lactation — Insufficient safety data exists for use during pregnancy or breastfeeding. While no teratogenic effects have been reported, use is discouraged in the absence of adequate reproductive safety studies.
- Pediatric use — Limited safety data in children. Use only under specialist supervision.
- Known hypersensitivity — Discontinue use if signs of allergic reaction (rash, urticaria, angioedema) develop, though allergic reactions to Ta1 are rare.
Standard Protocols
The following protocols include both the internationally approved dosing regimen (Zadaxin) and community-reported protocols. The 1.6 mg twice-weekly regimen is the standard approved dose in countries where Ta1 is registered. Thymosin alpha-1 is not FDA-approved in the United States.
| Protocol | Route | Dose | Frequency | Duration |
|---|---|---|---|---|
| Hepatitis B (approved regimen) | SubQ | 1.6 mg | 2x/week | 6–12 months |
| Cancer adjunct | SubQ | 1.6 mg | 2x/week | Duration of chemotherapy cycle + maintenance |
| Immune support (general) | SubQ | 1.6 mg | 2x/week | 4–12 weeks |
| Acute illness / infection (intensive) | SubQ | 1.6 mg | 1x daily | 7–14 days, then taper to 2x/week |
| Vaccine adjuvant | SubQ | 1.6 mg | 2x/week for 4 weeks surrounding vaccination | 4 weeks |
Common Stacks & Synergies
Thymosin alpha-1 has been combined with other agents in both clinical trials and community practice. Some combinations have published clinical evidence:
- Ta1 + Interferon-alpha — The most evidence-based combination. Clinical trials demonstrate improved HBeAg seroconversion rates in chronic hepatitis B when Ta1 is combined with interferon-alpha compared to either agent alone.[3]
- Ta1 + Chemotherapy — Used clinically in some countries as an immune adjunct during cancer chemotherapy to mitigate chemotherapy-induced immunosuppression and enhance antitumor immunity.[3]
- Ta1 + Immune checkpoint inhibitors — An area of active research. The rationale is that Ta1 enhances the T-cell response that checkpoint inhibitors (anti-PD-1, anti-CTLA-4) seek to unleash against tumors.
- Ta1 + BPC-157 — A community-discussed combination pairing Ta1's systemic immune support with BPC-157's tissue-repair properties. No published clinical evidence supports this combination.
- Ta1 + Vitamin D / Zinc — Commonly discussed as a general immune-support protocol. Both vitamin D and zinc support immune function independently, and may complement Ta1's immunomodulatory effects.
Preparation & Administration
Thymosin alpha-1 is available as Zadaxin (pharmaceutical-grade, approved in non-US markets) in pre-filled syringes containing 1.6 mg, or as a lyophilized powder from compounding pharmacies and research chemical suppliers. The compounded and research-grade versions require reconstitution.
Reconstitution
For lyophilized Ta1 from compounding pharmacies, reconstitute with bacteriostatic water according to the pharmacy's instructions. Typical compounding vial sizes range from 3 mg to 10 mg. For a 3 mg vial reconstituted with 1 mL of bacteriostatic water, each 0.53 mL delivers approximately 1.6 mg (the standard dose). For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.
Injection
Subcutaneous injections should be administered using a 29–31 gauge insulin syringe. Preferred injection sites include the abdomen (periumbilical area) and anterior thigh. Rotate injection sites to avoid lipodystrophy. For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.
Side Effects & Adverse Events
Thymosin alpha-1 has one of the most favorable safety profiles among immunomodulatory agents. Extensive clinical use across 35+ countries over multiple decades has established a strong safety record. The most commonly reported adverse effects are mild and injection-site related.
Ta1 has been generally very well-tolerated in clinical trials and post-marketing surveillance. Across multiple Phase 2/3 trials and decades of clinical use in countries where it is approved, the rate of serious adverse events attributable to Ta1 has been extremely low.[3][5]
Reported adverse events:
- Injection site redness and mild discomfort (most commonly reported; generally mild and self-limiting)
- Rare allergic reactions (urticaria, rash; very infrequent)
- Mild flu-like symptoms in initial doses (uncommon; typically resolve with continued use)
- Transient low-grade fever (rare)
- Mild fatigue (rare)
No dose-limiting toxicity has been identified in clinical studies. The favorable safety profile is consistent with Ta1 being a naturally occurring endogenous peptide that modulates rather than broadly stimulates the immune system.
Drug Interactions
Formal drug interaction studies are limited, but clinical experience from decades of use provides practical guidance:
- Immunosuppressants (cyclosporine, tacrolimus, mycophenolate) — Ta1's immune-enhancing effects may counteract immunosuppressive therapy. This combination should be avoided in transplant recipients and used with extreme caution in autoimmune disease managed with immunosuppressants.
- Interferon-alpha — Clinically used in combination with Ta1 for hepatitis B. The combination is well-characterized and generally well-tolerated, with evidence of additive efficacy.[3]
- Corticosteroids (systemic) — High-dose systemic corticosteroids suppress immune function and may blunt the immunomodulatory effects of Ta1. The clinical significance of this interaction depends on the dose and duration of corticosteroid therapy.
- Immune checkpoint inhibitors (nivolumab, pembrolizumab) — Theoretical additive immune activation. This combination is under active investigation in oncology and may increase both efficacy and immune-related adverse events.
- Vaccines — Ta1 may enhance vaccine immunogenicity. Clinical studies have shown improved vaccine response rates when Ta1 is co-administered with influenza and hepatitis B vaccines in immunocompromised populations.[5]
Storage & Handling
| Form | Condition | Stability |
|---|---|---|
| Zadaxin pre-filled syringe | Refrigerated (2–8°C / 36–46°F) | Per manufacturer labeling (typically 2–3 years) |
| Lyophilized powder (sealed) | Refrigerated (2–8°C / 36–46°F) | Optimal; stable for months to years if sealed |
| Lyophilized powder (sealed) | Room temperature (below 25°C / 77°F) | Stable for months if sealed and protected from light |
| Reconstituted solution | Refrigerated (2–8°C / 36–46°F) | Use within 28 days |
| Reconstituted solution | Room temperature | Not recommended; use within 24–48 hours if unavoidable |
Do not freeze reconstituted solution. Protect from prolonged light exposure. If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Always use bacteriostatic water (not sterile water) for reconstitution to provide antimicrobial preservation for multi-dose use.
Legal & Regulatory Status
- International approvals — Thymosin alpha-1 (as Zadaxin / thymalfasin) is approved for clinical use in over 35 countries, including China, India, South Korea, the Philippines, and many EU member states. Primary approved indications include chronic hepatitis B and as an immunotherapy adjunct in cancer.
- FDA (United States) — Not FDA-approved for any indication. An orphan drug application was filed but approval was not granted. The FDA has not approved Ta1 for hepatitis or cancer indications.
- US availability — Available in the United States through compounding pharmacies. Compounded Ta1 is legally prescribed by physicians as an off-label compounded medication.
- WADA (World Anti-Doping Agency) — Not specifically listed on the WADA Prohibited List as of 2026.
- China — Widely used and approved. Included in Chinese treatment guidelines for hepatitis B and was used as an adjunctive treatment during COVID-19.[4]
- Research chemical availability — Also available from research chemical suppliers, though the pharmaceutical-grade Zadaxin product and compounded versions from licensed pharmacies are preferred for quality assurance.
Open Questions
Despite decades of clinical use, several important questions about thymosin alpha-1 remain:
- FDA approval pathway — Whether Ta1 will ever receive FDA approval in the United States remains uncertain. The lack of US approval despite extensive international use and clinical data is partly attributed to the cost of conducting FDA-standard Phase 3 trials for a naturally occurring peptide.
- Optimal dosing for different indications — The standard 1.6 mg twice-weekly regimen was established for hepatitis B. Whether this dose is optimal for cancer immunotherapy adjunct, general immune support, or acute infection management is not well established.
- Duration of immune effects — How long the immunomodulatory effects of Ta1 persist after discontinuation is not precisely characterized. Some studies suggest sustained immune benefits for weeks to months after stopping treatment.
- Combination with modern immunotherapy — The interaction between Ta1 and immune checkpoint inhibitors is an active area of investigation that could significantly expand Ta1's clinical utility in oncology.
- Role in aging and immunosenescence — Whether Ta1 supplementation can meaningfully reverse age-related immune decline and reduce infection risk or cancer incidence in elderly populations is an important but insufficiently studied question.
- Compounded product quality — The consistency and purity of Ta1 from different compounding pharmacies in the US has not been systematically evaluated. Product quality may vary between sources.
Bibliography
- Goldstein AL, Goldstein AL. "From lab to bedside: emerging clinical applications of thymosin alpha 1." Expert Opin Biol Ther. 2009;9(5):593-608. doi:10.1517/14712590902911412. PMID:19392576.
- Romani L, Bistoni F, Montagnoli C, Gaziano R, Bozza S, Bonifazi P, Zelante T, Moretti S, Rasi G, Garaci E, Puccetti P. "Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance." Ann N Y Acad Sci. 2007;1112:326-38. doi:10.1196/annals.1415.002. PMID:17600285.
- Garaci E, Favalli C, Pica F, Sinibaldi Vallebona P, Palamara AT, Matteucci C, Pierimarchi P, Serafino A, Mastino A, Bistoni F, Romani L, Rasi G. "Thymosin alpha 1: from bench to bedside." Ann N Y Acad Sci. 2007;1112:225-34. doi:10.1196/annals.1415.044. PMID:17600276.
- Liu Y, Pang Y, Hu Z, Wu M, Wang C, Feng Z, Mao C, Tan Y, Liu Y, Chen L, Li M, Wang G, Yuan Z, Diao B, Chen Y. "Thymosin alpha 1 (Ta1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells." Clin Infect Dis. 2020;71(16):2150-2157. doi:10.1093/cid/ciaa630. PMID:32442287.
- Tuthill C, Rios I, McBeath R. "Thymalfasin: clinical pharmacology and antiviral applications." BioDrugs. 2010;24(1):7-16. doi:10.2165/11318790-000000000-00000. PMID:20055529.
- Garaci E. "Thymosin alpha1: a historical overview." Ann N Y Acad Sci. 2007;1112:14-20. doi:10.1196/annals.1415.039. PMID:17468230.